SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

AVC-203

LGND·Ligand Pharmaceuticals
NEUTRAL
Drug Impact Rating1/10
Trial phase
Phase 1/2
Time to market
Likely years away. The QUADvance Phase I/II trial's primary completion is estimated for April 2029. Even with potential accelerated development, regulatory filing would be at least several years away given the Phase 1a dose-escalation stage.
Why 1/10
No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) exists for AVC-203 within the next ~12 months. The Phase I/II QUADvance study is in early dose escalation (first patient dosed April 2026) with primary completion estimated at April 2029. For LGND, this is one of 200+ royalty assets and represents a small financial commitment ($41M total, paid in milestone-tied tranches). The next meaningful event would be early safety/efficacy data from Phase 1a, but no date is set.
Actionable Insight NEUTRAL

AVC-203 is in very early clinical testing (Phase 1a dose escalation), with no hard-dated binary catalysts on the horizon. The primary completion of the QUADvance study is estimated for April 2029. For LGND investors, this program is a minor, early-stage royalty interest among over 200 assets in Ligand's portfolio; watch for any early Phase 1a data disclosures at medical meetings, but the near-term stock thesis for LGND is determined by its established royalty portfolio and earnings trajectory, not this single program.

Price Chart

Loading chart...

Executive Summary

AVC-203 is a CRISPR-engineered allogeneic (off-the-shelf) CAR-T cell therapy being developed by private company AvenCell Therapeutics for relapsed or refractory B-cell malignancies (lymphomas and leukemias). It simultaneously targets CD19 and CD20 to reduce the chance of cancer relapse via antigen escape. The QUADvance Phase I/II trial received FDA IND clearance and EMA approval in December 2025, and the first patient was dosed in April 2026. Ligand Pharmaceuticals (Nasdaq: LGND) holds a financial interest via a September 2026 royalty financing agreement: up to $41 million committed in milestone-tied tranches in exchange for a mid-single-digit to low-double-digit royalty on worldwide net sales of AvenCell's pipeline, including AVC-203. For LGND, this is a small, early-stage, non-binary royalty interest within a portfolio of over 200 assets. No near-term pivotal catalysts are scheduled for AVC-203, and the primary completion of the Phase I/II study is estimated for April 2029.

How It Works

AVC-203 is an 'off-the-shelf' cell therapy made from healthy donor immune cells (T-cells) that have been genetically edited using CRISPR to target and kill cancer cells. It simultaneously targets two proteins on B-cell cancers called CD19 and CD20, which is designed to reduce the chance that cancer cells evade treatment by losing one target. The 'allogeneic' approach means these cells are pre-manufactured from healthy donors and ready to use immediately, unlike current CAR-T therapies that require extracting, engineering and reinfusing a patient's own cells, a process that takes weeks. A safety 'switch' is built in to allow deactivation if needed.

Trial Status

The FDA and EMA cleared the Phase I/II QUADvance study in December 2025. The first patient was dosed in April 2026, making it the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T to enter clinical testing. The study is actively recruiting at multiple sites in the US and Europe, with planned expansion to Japan. The estimated primary completion date is April 2029.

The Two-Sided Case

▲ Bull Case4
AVC-203 is the first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T to enter clinical testing, combining dual antigen targeting (to reduce relapse via antigen escape), immune-evasive engineering, and off-the-shelf convenience.
The dual-targeting CD19/CD20 approach addresses a key limitation of single-target CD19 CAR-Ts (relapse due to CD19 loss), and the allogeneic 'off-the-shelf' format could improve patient access vs. expensive, logistically complex autologous CAR-Ts.
Regulatory momentum is positive: both FDA (IND clearance) and EMA (CTA approval) allowed the QUADvance trial to proceed, and the first patient was dosed in April 2026, just 4 months after regulatory clearance.
Ligand's deal structure is low-risk: the $41 million commitment is milestone-tied (4 tranches), and the royalty is on worldwide net sales, providing leveraged upside if AVC-203 succeeds without Ligand bearing development risk.
▼ Bear Case4
Allogeneic CAR-T is a technically challenging field; several competitors have faced safety (cytokine release syndrome, neurotoxicity) and efficacy (persistence, rejection) hurdles in early trials.
AVC-203 faces intense competition from approved autologous CD19 CAR-Ts (Kymriah, Yescarta, Tecartus, Breyanzi) and other allogeneic programs from Allogene Therapeutics, Caribou Biosciences, and CRISPR Therapeutics.
The QUADvance Phase I/II study has an estimated primary completion date of April 2029; meaningful clinical data will take years, and early-stage cell therapy trials have a high attrition rate.
For LGND investors, the AVC-203 royalty interest is fractional; the $41M commitment is spread across the entire AvenCell pipeline, and the mid-single-digit to low-double-digit royalty rate will yield no revenue for years, if ever.

Upcoming Catalysts

  • No hard-dated catalysts are scheduled. The next meaningful event would be early Phase 1a safety/efficacy data from the QUADvance dose-escalation portion, potentially disclosed at medical conferences in 2027-2028. Ligand's milestone payments tied to AvenCell's clinical progress are not publicly dated events.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report

Sources · 8

Hover a chip for the title
1 investor.ligand.com2 avencell.com3 targetedonc.com4 avencell.com5 clinicaltrials.gov6 gosset.ai7 synapse.patsnap.com8 markets.businessinsider.com